{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073870","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.718062+00:00","generated_at":"2026-05-17T15:32:55.508482+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027","bullets":["SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.","Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.","Amended Toray license extends cartridge manufacturing timeline to October 2026.","SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.","No detailed financial results disclosed; company pre-revenue with clinical and operational progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073870","json":"https://secwatch.observer/filing/0001213900-25-073870.json","markdown":"https://secwatch.observer/filing/0001213900-25-073870.md","text":"https://secwatch.observer/filing/0001213900-25-073870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/0001213900-25-073870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/ea0252557-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:32:55.508482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}